Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Tolerability of Exenatide in Adolescent Subjects With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Treatment with diet and exercise alone or a stable dose of metformin, or sulfonylurea, or metformin plus a sulfonylurea for at least 3 months.~* Has HbA1c 6.0% to 11.0%, inclusive, at screening.~* Has a body weight of \>= 50 kg at screening.~Exclusion Criteria:~* Received any investigational drug or has participated in any type of clinical trial within 3 months prior to screening.~* Currently participates in any other interventional study.~* Is currently treated with any of the following excluded medications:~  * Sulfonylurea chlorpropamide~ * Thiazolidinedione within 3 months of screening.~ * Αlpha glucosidase inhibitor within 3 months of screening.~ * Meglitinide within 3 months of screening.~ * Insulin within 3 months of screening.~ * Pramlintide within 3 months of screening.

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 16 Years
- Healthy Volunteers: f

Study Arms:
- Sequence 1 (Type: EXPERIMENTAL): Exenatide 2.5 mcg - Exenatide 5 mcg - Placebo 0.02 mL
- Sequence 2 (Type: EXPERIMENTAL): Exenatide 2.5 mcg - Placebo 0.02 mL - Exenatide 5 mcg
- Sequence 3 (Type: EXPERIMENTAL): Placebo 0.02 mL - Exenatide 2.5 mcg - Exenatide 5 mcg

Based on this trial design, predict the completion outcome and termination type (if applicable).